Concepts (183)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiomyopathy, Dilated | 9 | 2006 | 219 | 1.570 |
Why?
|
| Glucagon | 4 | 2005 | 151 | 0.870 |
Why?
|
| Ventricular Dysfunction, Left | 4 | 2015 | 377 | 0.860 |
Why?
|
| Myocardium | 6 | 2006 | 908 | 0.770 |
Why?
|
| Coronary Circulation | 6 | 2005 | 207 | 0.730 |
Why?
|
| Peptide Fragments | 4 | 2005 | 800 | 0.660 |
Why?
|
| Hemodynamics | 5 | 2015 | 855 | 0.600 |
Why?
|
| Dogs | 11 | 2006 | 657 | 0.510 |
Why?
|
| Vasodilator Agents | 3 | 2015 | 207 | 0.500 |
Why?
|
| Sildenafil Citrate | 1 | 2015 | 57 | 0.450 |
Why?
|
| Glucagon-Like Peptide 1 | 5 | 2006 | 74 | 0.450 |
Why?
|
| Metoprolol | 2 | 2006 | 21 | 0.430 |
Why?
|
| Oxygen Consumption | 3 | 2004 | 305 | 0.420 |
Why?
|
| Protein Precursors | 2 | 2004 | 156 | 0.410 |
Why?
|
| Myocardial Contraction | 3 | 2004 | 256 | 0.400 |
Why?
|
| Catecholamines | 2 | 2004 | 52 | 0.400 |
Why?
|
| Nitric Oxide | 3 | 2005 | 471 | 0.370 |
Why?
|
| Glucose | 3 | 2005 | 878 | 0.370 |
Why?
|
| Ventricular Function, Left | 4 | 2015 | 551 | 0.360 |
Why?
|
| Antihypertensive Agents | 1 | 2015 | 429 | 0.360 |
Why?
|
| Hypertension, Pulmonary | 1 | 2015 | 460 | 0.320 |
Why?
|
| Exercise | 1 | 2015 | 857 | 0.290 |
Why?
|
| Glucagon-Like Peptides | 2 | 2005 | 37 | 0.280 |
Why?
|
| Stroke Volume | 5 | 2015 | 541 | 0.280 |
Why?
|
| Myocardial Stunning | 2 | 2004 | 19 | 0.270 |
Why?
|
| Adrenergic Antagonists | 1 | 2006 | 4 | 0.250 |
Why?
|
| Propanolamines | 1 | 2006 | 19 | 0.250 |
Why?
|
| Carbazoles | 1 | 2006 | 30 | 0.250 |
Why?
|
| Heart Transplantation | 3 | 2024 | 877 | 0.240 |
Why?
|
| Endothelium-Dependent Relaxing Factors | 1 | 2005 | 5 | 0.230 |
Why?
|
| Myocardial Infarction | 2 | 2004 | 1048 | 0.230 |
Why?
|
| Nitric Oxide Synthase | 2 | 2002 | 175 | 0.230 |
Why?
|
| Insulin Resistance | 3 | 2004 | 697 | 0.220 |
Why?
|
| Adrenergic beta-Agonists | 4 | 2006 | 78 | 0.210 |
Why?
|
| Cardiac Tamponade | 1 | 2004 | 38 | 0.210 |
Why?
|
| Thiazolidinediones | 1 | 2004 | 81 | 0.210 |
Why?
|
| Pericardial Effusion | 1 | 2004 | 73 | 0.210 |
Why?
|
| Heart Ventricles | 2 | 2005 | 791 | 0.210 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2004 | 129 | 0.200 |
Why?
|
| Enalaprilat | 1 | 2002 | 2 | 0.190 |
Why?
|
| Receptors, Bradykinin | 1 | 2002 | 4 | 0.190 |
Why?
|
| Heart Failure | 3 | 2004 | 2393 | 0.190 |
Why?
|
| Bradykinin | 1 | 2002 | 50 | 0.190 |
Why?
|
| Hepacivirus | 1 | 2004 | 272 | 0.190 |
Why?
|
| Endothelium, Vascular | 1 | 2005 | 487 | 0.190 |
Why?
|
| Angina, Unstable | 1 | 2002 | 52 | 0.190 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2004 | 323 | 0.180 |
Why?
|
| Peptides | 1 | 2005 | 847 | 0.180 |
Why?
|
| Muscle Proteins | 1 | 2004 | 407 | 0.170 |
Why?
|
| Consciousness | 4 | 2005 | 46 | 0.170 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2002 | 222 | 0.170 |
Why?
|
| Patient Selection | 1 | 2024 | 737 | 0.170 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2002 | 224 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2005 | 1672 | 0.160 |
Why?
|
| Isoproterenol | 3 | 2006 | 97 | 0.160 |
Why?
|
| Hypoglycemic Agents | 1 | 2004 | 482 | 0.160 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2004 | 613 | 0.160 |
Why?
|
| Hypersensitivity | 1 | 2002 | 196 | 0.160 |
Why?
|
| Cardiac Pacing, Artificial | 3 | 2005 | 129 | 0.150 |
Why?
|
| Cardiomyopathies | 1 | 2004 | 518 | 0.150 |
Why?
|
| Animals | 11 | 2006 | 34882 | 0.120 |
Why?
|
| Diabetes Mellitus | 1 | 2004 | 921 | 0.120 |
Why?
|
| Hyperparathyroidism | 1 | 1995 | 26 | 0.120 |
Why?
|
| Liver Transplantation | 1 | 2004 | 1103 | 0.120 |
Why?
|
| Point-of-Care Testing | 1 | 2015 | 33 | 0.110 |
Why?
|
| Diabetes Complications | 3 | 2006 | 206 | 0.110 |
Why?
|
| Male | 14 | 2015 | 64922 | 0.110 |
Why?
|
| Pancreatitis | 1 | 1995 | 140 | 0.110 |
Why?
|
| Exercise Tolerance | 1 | 2015 | 90 | 0.110 |
Why?
|
| Transcription Factors | 1 | 2004 | 2493 | 0.110 |
Why?
|
| Fatty Acids, Nonesterified | 2 | 2004 | 116 | 0.100 |
Why?
|
| Vasodilation | 2 | 2005 | 182 | 0.100 |
Why?
|
| Exercise Test | 1 | 2015 | 259 | 0.100 |
Why?
|
| Regional Blood Flow | 2 | 2006 | 212 | 0.100 |
Why?
|
| Adrenergic alpha-Agonists | 2 | 2004 | 19 | 0.100 |
Why?
|
| Medical Staff, Hospital | 1 | 2013 | 98 | 0.100 |
Why?
|
| Dobutamine | 2 | 2004 | 56 | 0.100 |
Why?
|
| Norepinephrine | 2 | 2004 | 166 | 0.100 |
Why?
|
| Nitroarginine | 2 | 2002 | 8 | 0.090 |
Why?
|
| Lactic Acid | 2 | 2004 | 156 | 0.090 |
Why?
|
| Heart Rate | 2 | 2006 | 591 | 0.090 |
Why?
|
| Treatment Outcome | 5 | 2015 | 13028 | 0.090 |
Why?
|
| Heart | 2 | 2006 | 700 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2013 | 492 | 0.090 |
Why?
|
| Models, Animal | 2 | 2004 | 470 | 0.090 |
Why?
|
| Cardiac Catheterization | 1 | 2015 | 664 | 0.080 |
Why?
|
| Blood Glucose | 2 | 2004 | 1123 | 0.080 |
Why?
|
| Disease Models, Animal | 3 | 2004 | 4688 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 2320 | 0.080 |
Why?
|
| Blood Pressure | 2 | 2005 | 1400 | 0.070 |
Why?
|
| Enzyme Inhibitors | 2 | 2002 | 588 | 0.070 |
Why?
|
| Female | 11 | 2013 | 70712 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2013 | 768 | 0.070 |
Why?
|
| Cardiac Output, Low | 1 | 2006 | 62 | 0.060 |
Why?
|
| Algorithms | 1 | 2013 | 1728 | 0.060 |
Why?
|
| Plasmapheresis | 1 | 2006 | 33 | 0.060 |
Why?
|
| Middle Aged | 5 | 2015 | 28964 | 0.060 |
Why?
|
| Nitric Oxide Donors | 1 | 2005 | 20 | 0.060 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2006 | 150 | 0.060 |
Why?
|
| Nicardipine | 1 | 2005 | 17 | 0.060 |
Why?
|
| Nitroglycerin | 1 | 2005 | 23 | 0.060 |
Why?
|
| Acetylcholine | 1 | 2005 | 84 | 0.060 |
Why?
|
| Calcium Channel Blockers | 1 | 2005 | 118 | 0.060 |
Why?
|
| Vasoconstrictor Agents | 1 | 2005 | 141 | 0.060 |
Why?
|
| Heart-Lung Transplantation | 1 | 2024 | 24 | 0.060 |
Why?
|
| Glucose Clamp Technique | 1 | 2004 | 76 | 0.050 |
Why?
|
| Adenosine | 1 | 2005 | 135 | 0.050 |
Why?
|
| Hyperinsulinism | 1 | 2004 | 62 | 0.050 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2004 | 152 | 0.050 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2004 | 20 | 0.050 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2004 | 43 | 0.050 |
Why?
|
| Cocaine | 1 | 2005 | 214 | 0.050 |
Why?
|
| Cytosol | 1 | 2004 | 144 | 0.050 |
Why?
|
| Neurotransmitter Agents | 1 | 2004 | 143 | 0.050 |
Why?
|
| Echocardiography, Doppler | 1 | 2004 | 172 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2006 | 1450 | 0.050 |
Why?
|
| Safety | 1 | 2004 | 216 | 0.050 |
Why?
|
| Humans | 10 | 2024 | 132061 | 0.050 |
Why?
|
| Chronic Disease | 2 | 2006 | 1234 | 0.050 |
Why?
|
| Models, Cardiovascular | 1 | 2004 | 184 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2004 | 547 | 0.050 |
Why?
|
| Adenosine Triphosphate | 1 | 2004 | 275 | 0.050 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2004 | 183 | 0.050 |
Why?
|
| Blood Flow Velocity | 1 | 2004 | 442 | 0.050 |
Why?
|
| Receptor, Bradykinin B2 | 1 | 2002 | 1 | 0.050 |
Why?
|
| Waiting Lists | 1 | 2024 | 237 | 0.050 |
Why?
|
| Losartan | 1 | 2002 | 35 | 0.050 |
Why?
|
| Stimulation, Chemical | 1 | 2002 | 43 | 0.050 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2002 | 50 | 0.050 |
Why?
|
| Phenylephrine | 1 | 2002 | 40 | 0.050 |
Why?
|
| Cell Respiration | 1 | 2001 | 24 | 0.050 |
Why?
|
| Fatty Acids | 1 | 2004 | 356 | 0.050 |
Why?
|
| Glycogen | 1 | 2001 | 53 | 0.050 |
Why?
|
| Myocardial Revascularization | 1 | 2002 | 105 | 0.040 |
Why?
|
| Blotting, Western | 1 | 2004 | 1077 | 0.040 |
Why?
|
| Tachycardia | 1 | 2001 | 69 | 0.040 |
Why?
|
| Tobacco Use Disorder | 1 | 2002 | 87 | 0.040 |
Why?
|
| Myocardial Ischemia | 1 | 2004 | 343 | 0.040 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2002 | 137 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2004 | 500 | 0.040 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2001 | 192 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 1347 | 0.040 |
Why?
|
| Kinetics | 1 | 2002 | 1130 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2004 | 1294 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2004 | 1608 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2024 | 778 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2002 | 1009 | 0.040 |
Why?
|
| Hepatitis C, Chronic | 1 | 2004 | 370 | 0.040 |
Why?
|
| Coronary Angiography | 1 | 2002 | 485 | 0.040 |
Why?
|
| Energy Metabolism | 1 | 2004 | 785 | 0.040 |
Why?
|
| Pacemaker, Artificial | 1 | 2001 | 192 | 0.040 |
Why?
|
| Syndrome | 1 | 2002 | 1174 | 0.040 |
Why?
|
| Adult | 4 | 2013 | 31568 | 0.040 |
Why?
|
| Insulin | 1 | 2004 | 1168 | 0.040 |
Why?
|
| Cytokines | 1 | 2004 | 1358 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2004 | 2674 | 0.030 |
Why?
|
| Aged | 3 | 2006 | 21406 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2004 | 3091 | 0.030 |
Why?
|
| Hypercalcemia | 1 | 1995 | 42 | 0.030 |
Why?
|
| Drug Administration Schedule | 2 | 2006 | 749 | 0.030 |
Why?
|
| Risk Factors | 2 | 2013 | 10941 | 0.030 |
Why?
|
| Hypertension | 1 | 2002 | 1396 | 0.030 |
Why?
|
| Alcoholism | 1 | 1995 | 249 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2004 | 7102 | 0.020 |
Why?
|
| Acute Disease | 1 | 1995 | 1160 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2004 | 3834 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2013 | 792 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2004 | 3142 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2002 | 1408 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 1131 | 0.020 |
Why?
|
| Survival Rate | 1 | 2013 | 2192 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2006 | 127 | 0.020 |
Why?
|
| Isoantibodies | 1 | 2006 | 58 | 0.020 |
Why?
|
| Histocompatibility Testing | 1 | 2006 | 110 | 0.020 |
Why?
|
| Hypoglycemia | 1 | 2006 | 183 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2013 | 5164 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 2006 | 357 | 0.010 |
Why?
|
| Biopsy | 1 | 2006 | 1284 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2006 | 1573 | 0.010 |
Why?
|
| Graft Rejection | 1 | 2006 | 559 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2006 | 672 | 0.010 |
Why?
|
| Quality of Life | 1 | 2006 | 2137 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2013 | 17419 | 0.010 |
Why?
|